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Aim: Although there is evidence of a positive association between psoriasis and body mass index (BMI) and
leptin is known to play a part in the regulation of the immune system, the relationship between psoriasis and
leptin is still not well known. The aim of this study was to evaluate the possible relation between leptin and
psoriasis.
Materials and Methods: Serum leptin concentrations and BMI in 20 patients with psoriasis were compared
to 20 age- and sex-matched healthy volunteers.
Results: There was no difference between serum leptin levels of psoriatic patients (32.3 ± 24.9 ng/ml) and
controls (36.8 ± 28.2 ng/ml). Leptin levels of both psoriatic and healthy volunteers showed positive
correlations with BMI. Serum leptin levels in the patient group did not correlate with psoriasis area severity
index (PASI) score or duration of psoriasis.
Conclusions: In the setting of this study, our results did not support any possible relation between serum
leptin levels and psoriasis.
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Amaç: Psöriasis, ile vücut kitle indeksi (VK‹) aras›ndaki iliﬂki ve leptinin immun sistem düzenlenmesindeki rolü
hakk›nda bilgimiz olmas›na ra¤men, psöriasis ve leptin aras›ndaki iliﬂki hakk›nda kesin bir bilgimiz yok.
Çal›ﬂmam›z›n amac›, psöriasis ve leptin aras›ndaki olas› iliﬂkiyi incelemektir.
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Yöntemler: Yirmi psöriasisli hasta ile yaﬂ ve cins bak›m›ndan uyumu 20 sa¤l›kl› bireyde serum leptin ve VK‹
de¤erleri karﬂ›laﬂt›r›ld›.
Bulgular: Serum leptin düzeyleri psöriasisli (32.3 ± 24.9 ng/ml) hasta grubu ve kontrol grubunda (36.8 ±
28.2 ng/ml) farkl› bulunmad›. Her iki grupta da serum leptin düzeyleri ile VK‹ aras›nda pozitif korelasyon
saptand›. Hasta grubunda serum leptin düzeyleri psoriasis alan ﬂiddet indeksi (PAﬁ‹) ve hastal›k süresi ile iliﬂkili
bulunmad›.
Sonuç: Çal›ﬂmam›zdan elde etti¤imiz sonuçlar psöriasis ve leptin düzeyleri aras›nda herhangi bir iliﬂki
olmad›¤›n› göstermektedir.
Anahtar Sözcükler: Psoriasis, leptin, VK‹
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Psoriasis is a chronic inflammatory skin disease characterized by marked increases in
keratinocyte proliferation, prominent alterations in dermal capillary vasculature and the
presence of dermal and epidermal T cells, monocytes/macrophages and neutrophils (1).
Although the influence of environmental factors on psoriasis is not defined precisely,
body mass index (BMI) has been reported to be one of the important associated factors,
and a positive association between BMI and psoriasis has been shown (2,3). Leptin, a
protein secreted by the adipose tissue, has important roles in metabolism and immunity;
it regulates body weight and exerts other biologic functions that modulate
hematopoiesis, angiogenesis and immune responses (4). Additionally, leptin mediates
proliferative and antiapoptotic activities in different cell types including T cells (5) and
eosinophils (6). Leptin is also linked to energy storage, and it was also reported that
serum leptin levels show a positive correlation with BMI and reflect the body fat mass
(7). Leptin receptor is expressed primarily in the hypothalamus, but it is also expressed
by peripheral blood mononuclear cells, vascular endothelial cells, smooth muscle cells,
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osteoblasts and fibroblasts. Leptin produced by
fibroblasts may thus exert important local autocrine and
paracrine actions (8). Since psoriasis is an immunemediated inflammatory disease, characterized by
hyperproliferation of keratinocytes and infiltration of
mostly T lymphocytes, leptin may provide a link between
T cell function and inflammation in psoriasis.
In our preliminary study, we assessed serum leptin
levels in patients with psoriasis and healthy controls. The
aim of this study was to evaluate a possible relation
between leptin and psoriasis.
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All statistical analyses were performed by means of
SPSS statistical software package for Windows (version
11.0; SPSS Inc., Chicago, Illinois). The gender, age and
BMI of the groups were compared by chi-square test and
leptin levels by Mann-Whitney U test.

Results
Demographic features and serum leptin levels in
psoriatic patients and controls are given in Table 1.
Table 1.

Demographic features and serum leptin levels in psoriatic
patients and controls.

Materials and Methods
Twenty consecutive patients with psoriasis who
admitted to the dermatology outpatient clinic in
Pamukkale University School of Medicine and 20 healthy
controls were enrolled in this study. Psoriasis was
diagnosed clinically and/or histopathologically. Patients
with a history of topical or systemic antipsoriatic therapy
within four weeks were not included in the study.
Subjects with a history of acute or chronic infection,
chronic renal or liver disease, diabetes mellitus, coronary
heart disease, hypertension, peripheral or cerebral
vascular disease, hypothyroidism, bronchial asthma or
chronic obstructive lung disease were also not included.
All of the subjects were non-smokers and none was
taking any systemic medication. No individual in the
psoriasis or control group was following a special dietary
regimen.
Anthropometric measurements were done by the
same physician on the day blood specimen was taken.
Height and weight of the subjects were obtained in light
clothing without shoes. Height was measured as the
distance from the top of the head to the bottom of the
feet (no shoes) using a fixed stadiometer. BMI was
calculated as the weight (kg) divided by square of the
height (m). Psoriasis area and severity index (PASI) score
was determined in each patient.
Venous blood samples were drawn from the
participants after a 12-h fast between 08:00 and 10:00
a.m. Samples were collected in serum separator tubes,
allowed to clot for 30 min, and centrifuged for 15 min at
2000x g at room temperature; serum was collected and
stored at -70 °C until analyzed. Serum leptin level was
determined by ELISA method using a commercial kit
(Diagnostic System Lab, USA). Informed consent was
obtained from each subject.
136

Patients (n=20)
Female/Male

Controls (n=20)

8/12

10/10

Age

48.0 ± 8.8

50.9 ± 11.4

PASI score (years)

6.2 ± 6.0

-

Duration of psoriasis (years) 18.1 ± 14.9
2
BMI (kg/m )

Leptin (ng/ml)

28.1 ± 5.0

25.6 ± 3.6

32.3 ± 24.9

36.8 ± 28.2

PASI: Psoriasis area severity index.

Plaque psoriasis was the most common clinical form
(75%) and in the remaining cases, clinical form was
consistent with guttata psoriasis (25%). The mean PASI
score and age of onset of disease in the psoriasis group
were 6.2 ± 6.0 years and 29.9 ± 14.2 years,
respectively. Duration of psoriasis ranged from 0.5 to 45
years (18.1 ± 14.9 years).
There was no difference between serum leptin levels
of psoriatic patients and controls. Leptin levels of
psoriatic patients and healthy volunteers showed positive
correlations with BMI (r=0.551, p=0.012 and r=0.559,
p=0.010, respectively), but serum leptin levels in the
patient group correlated with neither PASI scores nor the
duration of psoriasis.

Discussion
Body mass index is a complex variable that seems to
affect immunity. It has been documented that circulatory
levels of tumor necrosis factor-alpha (TNF-α) and soluble
TNF-α receptors and in vitro TNF-α production are
significantly increased in obese as compared with nonobese subjects (9,10). In addition, Tanaka et al. (10)
detected a reduction in the population and function of
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two major subsets of T cells (CD4+Th, CD8+Tsc) in
obesity followed by a recovery after adequate weight
loss. BMI was reported to be independently correlated
with psoriasis in a case-controlled study that assessed the
risk factors associated with psoriasis (2). BMI ≥25 has
also been reported to have significant effects on longterm prognosis of plaque psoriasis after diagnosis (11).
Leptin (OB protein) is a 16 kDa adipokine, which was
initially described as an adipocyte-derived hormone. The
adipose tissue is a major source of leptin and its
circulating concentrations indirectly reflect body fat
stores. Leptin is an important signal in the regulation of
food intake and energy balance and its levels usually
correlate with BMI (7). It links nutritional status with
neuroendocrine and immune functions, and its role in the
modulation of immune response and inflammation has
recently become increasingly evident. The increase in
leptin production that occurs during infection and
inflammation strongly suggests that leptin is a part of the
cytokine network that governs the inflammatory-immune
response and the host defense mechanisms. Leptin plays
an important role in inflammatory processes involving T
cells and has been reported to modulate T-helper cell
activity in the cellular immune response (4). Hence, leptin
has a dual role in inflammation: it activates
monocyte/macrophage cells and potentiates production of
the proinflammatory cytokines, TNF-α, interleukin (IL)-6
and 9, and directs T cell differentiation to Th1 phenotype,
expressing interferon (INF)-γ and IL-2. On the other
hand, it expresses certain anti-inflammatory properties by
releasing IL-1 receptor antagonist (12,13). Several
studies have implicated leptin in the pathogenesis of
autoimmune inflammatory conditions, such as
rheumatoid arthritis (RA). In patients with RA, it is
reported that fasting leads to an improvement in disease
activity, which was associated with a marked decrease in
serum leptin and a shift towards Th2 cytokine production
(14). Other studies showed that serum levels of leptin
were not increased in patients with RA as compared with
controls. In addition, no correlation was detected
between leptin levels and disease activity, whereas a
positive correlation was seen between leptin and BMI or
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the percentage of body fat (15,16). Thus, it was
concluded that although leptin levels cannot be used to
assess disease activity in rheumatic diseases, existing data
warrants longitudinal studies to assess the potential
influence of leptin on disease outcome (17). Recently, a
significant inverse correlation between inflammation and
leptin concentrations was reported in patients with active
RA. Plasma leptin concentration was not found to be
significantly different from that in healthy controls, so the
authors suggested that active chronic inflammation may
lower plasma leptin concentrations (18).
In psoriasis, an effector-immune response develops to
unknown skin antigens and T cell activation is mainly of
type 1 cytokine pattern. INF-γ production induces
activation of keratinocytes and endothelial cells and it also
induces production of inflammatory cytokines (IL-1, TNFα) and chemokines (IL-8) (19). TNF-α, other cytokines
such as IL-6 and growth factors are involved in the
pathogenesis of psoriasis and in the mechanism of
hyperproliferation. Serum levels of these compounds can
be related to disease activity (20). Since leptin promotes
Th1 cell differentiation and cytokine production with
levels showing a positive correlation with BMI, we aimed
to investigate serum leptin levels in psoriasis. In our
study, serum leptin levels were found to be similar in
patients with psoriasis and healthy controls. Correlation
analysis in our patient group also did not reveal any
statistically significant correlations between serum leptin
levels and PASI scores. Leptin levels of both psoriatic and
healthy volunteers showed positive correlations with BMI,
as expected. A MEDLINE search failed to reveal any
studies investigating serum leptin levels in psoriasis.
Insulin secretion and sensitivity were investigated in
psoriasis and the values were found to be similar between
patients and controls (21).
In conclusion, in the setting of this study, our results
did not support any possible relation between serum
leptin levels and psoriasis. Considering the relatively small
number of subjects with relatively low mean PASI scores
in our patient group, further studies investigating severe
inflammatory forms of psoriasis (including erythroderma)
seem to be essential.

References
1.

Ortonne JP. Recent developments in the understanding of the
pathogenesis of psoriasis. Br J Dermatol 1997; 140: 1-7.

2.

Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A,
Virgili AR et al. Cigarette smoking, body mass index, and stressful
life events as risk factors for psoriasis: results from an Italian
case-control study. J Invest Dermatol 2005; 125: 61-67.

137

AKTAN, ﬁ et al.

Leptin and Psoriasis

Turk J Med Sci

3.

Naldi L, Parazzini F, Peli L, Chatenoud L, Cainelli T. Dietary factors
and the risk of psoriasis. Results of an Italian case-control study.
Br J Dermatol 1996; 134: 101-106.

13.

Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold
KR et al. Leptin deficiency enhances sensitivity to endotoxininduced lethality. Am J Physiol 1999; 276: R136-R142.

4.

Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino
JJ et al. Leptin from fat to inflammation: old questions and new
insights. FEBS Lett 2005; 579: 295-301.

14.

5.

Fujita Y, Murakami M, Ogawa Y, Masuzaki H, Tanaka M, Ozaki S
et al. Leptin inhibits stress-induced apoptosis of T lymphocytes.
Clin Exp Immunol 2002; 128: 21-26.

Fraser DA, Thoen J, Reseland JE, Forre O, Kjeldsen-Kragh J.
Decreased CD4+ lymphocyte activation and increased interleukin4 production in peripheral blood of rheumatoid arthritis patients
after acute starvation. Clin Rheumatol 1999; 18: 394-401.

15.

Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M.
Leptin serum levels are not correlated with disease activity in
patients with rheumatoid arthritis. Metabolism 1999; 48: 745748.

16.

Nishiya K, Nishiyama M, Chang A, Shinto A, Hashimoto K. Serum
leptin levels in patients with rheumatoid arthritis are correlated
with body mass index. Rinsho Byori 2002; 50: 524-527
(abstract).

17.

Palmer G, Gabay C. A role for leptin in rheumatic disease? Ann
Rheum Dis 2003; 62: 913-915.

18.

Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der
Meer JW. Markers of inflammation are negatively correlated with
serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64:
1195-1198.

19.

Robert C, Kupper TS. Inflammatory skin diseases, T cells and
immune surveillance. N Engl J Med 1999; 341: 1817-1828.

20.

Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol
1999; 38: 241-251.

21.

Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR,
Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin
secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol
2003; 48: 882-885.

6.

Conus C, Bruno A, Simon HU. Leptin is an eosinophil survivor
factor. J Allergy Clin Immunol 2005; 116: 1128-1134.

7.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens
TW, Nyce MR et al. Serum immunoreactive-leptin concentrations
in normal-weight and obese humans. N Engl J Med 1996; 334:
292-295.

8.

Glasow A, Kiess W, Anderegg U, Berthold A, Bottner A, Kratzsch
J. Expression of leptin (Ob) and leptin receptor (Ob-R) in human
fibroblasts: regulation of leptin secretion by insulin. J Clin
Endocrinol Metab 2001; 86: 4472-4479.

9.

10.

Tanaka S, Inoue S, Isoda F, Waseda M, Ishihara M, Yamakawa T
et al. Impaired immunity in obesity: suppressed but reversible
lymphocyte responsiveness. Int J Obes Relat Metab Disord 1993;
17: 631-636.
Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T
lymphopaenia in relation to body mass index and TNF-alpha in
human obesity: adequate weight reduction can be corrective. Clin
Endocrinol 2001; 54: 347-354.

11.

Sakai R, Matsui S, Fukushima M, Yasuda H, Miyachi Y. Prognostic
factor analysis for plaque psoriasis. Dermatology 2005; 11: 103106.

12.

Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA.
Leptin directly induces the secretion of interleukin 1 receptor
antagonist in human monocytes. J Clin Endocrinol Metab 2001;
86: 783-791.

138

